NCT01909804 - Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection | Biotech Hunter

Enrollment

323

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

August 31, 2014

Conditions

Hepatitis C

Interventions

DRUG

SOF

400 mg tablet administered orally once daily

DRUG

VEL

Tablet administered orally once daily

DRUG

RBV

200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (49)

Unknown

Long Beach

Los Angeles

Pasadena

San Diego

Denver

Gainesville

Jacksonville

Miami

Orlando

Tampa

Wellington

Atlanta

Marietta

Chicago

Indianapolis

Baltimore

Boston

Detroit

Hillsborough

Santa Fe

Great Neck

New York

Asheville

Durham

Fayetteville

Winston-Salem

Portland

Philadelphia

Pittsburgh

Providence

Germantown

Nashville

Arlington

Dallas

San Antonio

Annandale

Fairfax

Newport News

Norfolk

Seattle

Camperdown

Darlinghurst

Clayton

Melbourne

Fremantle

Perth

Auckland

Christchurch

San Juan